Krystal Biotech, Inc. (KRYS) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 17 analysts10.2% Above Target
KRYS trades 10.2% above Wall Street's consensus target of $336.40.
Current Price$374.68
Average Target$336.40
Target
Current
Low$300.00
Median$327.00
High$371.00
Analyst Target Range
Forward P/E48.8x
(Growth Premium)
PEG Ratio—
Implied Growth+4.0%
(Low)
Analyst Spread21.1%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes KRYS achieves its forward estimates and maintains a stable P/E multiple of 48.8x. This scenario reflects the blended consensus of 17 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
KRYS Price Target Analysis
Updated July 7, 2026As of July 7, 2026, Krystal Biotech, Inc. (KRYS) has a Wall Street consensus price target of $336.40, based on estimates from 17 covering analysts. With the stock currently trading at $374.68, this represents a potential downside of -10.2%. The company has a market capitalization of $11.05B.
Analyst price targets range from a low of $300.00 to a high of $371.00, representing a 21% spread in expectations. The median target of $327.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KRYS trades at a trailing P/E of 54.8x and forward P/E of 48.8x. Analysts expect EPS to grow +4.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $405.81, with bear and bull scenarios of $255.66 and $534.69 respectively. Model confidence stands at 60/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+992.8%
Industry Consensus
Avg Forward P/E
52.6x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCKTRocket Pharmaceuticals, Inc. | $436M | $3.99 | $5.00 | +25.3% | Buy | — | 19 |
 RAREUltragenyx Pharmaceutical Inc. | $3.3B | $33.70 | $47.11 | +39.8% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.77 | $34.38 | +33.4% | Buy | 67.7x | 37 |
 PTCTPTC Therapeutics, Inc. | $7.1B | $85.44 | $95.83 | +12.2% | Buy | 96.4x | 26 |
 SRPTSarepta Therapeutics, Inc. | $2.0B | $19.18 | $25.14 | +31.1% | Buy | 5.4x | 54 |
 CRSPCRISPR Therapeutics AG | $6.0B | $61.89 | $71.67 | +15.8% | Buy | — | 38 |
 EDITEditas Medicine, Inc. | $357M | $3.65 | $5.00 | +37.0% | Buy | — | 25 |
 BEAMBeam Therapeutics Inc. | $3.6B | $35.32 | $48.00 | +35.9% | Buy | — | 27 |
 SGMOSangamo Therapeutics, Inc. | $31M | $0.07 | $7.25 | +9697.3% | Hold | — | 14 |
KRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
What is the KRYS stock price target for 2026?
KRYS's consensus price target is $336.4, -10.2% below the current price of $374.68. The 17 analysts tracking KRYS see downside risk at present valuations.
Is KRYS a buy, sell, or hold?
KRYS has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $336.4 implies -10.2% downside from current levels.
Is KRYS stock overvalued or undervalued?
At a forward P/E of 48.8208x, KRYS trades at a premium valuation. The consensus price target of $336.4 (-10.2% downside) suggests analysts may view current valuations as stretched.
How high can KRYS stock go?
The most bullish Wall Street analyst has a price target of $371 for KRYS, while the most conservative target is $300. The consensus of $336.4 represents the median expectation. Our quantitative valuation model projects a bull case target of $535 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover KRYS stock?
KRYS is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the KRYS stock forecast?
The 12-month KRYS stock forecast based on 17 Wall Street analysts shows a consensus price target of $336.4, with estimates ranging from $300 (bear case) to $371 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $406, with bear/bull scenarios of $256/$535.
What is KRYS's fair value based on fundamentals?
Our quantitative valuation model calculates KRYS's fair value at $406 (base case), with a bear case of $256 and bull case of $535. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 60/100.
What is KRYS's forward P/E ratio?
KRYS trades at a forward P/E ratio of 48.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 54.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy KRYS stock?
Analysts are cautious on KRYS, with 0 Sell ratings and a price target of $336.4 (-10.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do KRYS price targets vary so much?
KRYS analyst price targets range from $300 to $371, a 21% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $336.4 consensus represents the middle ground. Our model's $256-$535 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare